Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

CNBC's Michael Ozanian discusses why a potential Boston Celtics sale might not happen until next year and the reason why the ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

On Thursday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $87.59 which represents a decrease of $-1.18 or -1.33% from the prior close of $88.77. The stock opened at ...

Meeting to be held on November 15 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

We recently compiled a list of the 8 Hot Growth Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results ...

On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share. Sales were $4.209 billion, up 19.4% from $3.527 billion in the prior ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.